NanoViricides 在印度完成第一阶段临床试验。 NanoViricides completes Phase I clinical trial in India.

NanoViricides 报告称，第一阶段 NV-387 临床试验在印度成功完成，预计很快锁定数据。 NanoViricides reports Phase I NV-387 clinical trial completed successfully in India, with data lock expected soon. 该试验已获准供健康和新冠肺炎患者参加，尽管增加了第二个试验点，但由于试验点缺乏合适的新冠肺炎病例，该试验被关闭。 The trial, approved for healthy and COVID-19 participants, was closed due to lack of suitable COVID-19 cases at trial sites despite a second site addition. 该公司是抗病毒纳米药物领域的领先者，计划分析试验数据以推进 NV-387 的开发。 The Company, a leader in antiviral nanomedicines, plans to analyze trial data to advance development of NV-387.